Patient Education Blog

Apixaban (Eliquis): Another New Oral “Blood Thinner”

Good news. Another one of the new oral ”blood thinners” in development,  Apixaban (Eliquis®), has moved forward. On May 23rd, 2011 the European Medicines Agency (EMA) approved Eliquis® for marketing in the 27 countries of the European Community for DVT prevention after orthopedic surgery (hip and knee replacement). In the U.S., Eliquis® is not yet FDA approved, and still some way away from approval.Eliquis® is a “blood thinner” that has the same advantages as the other new oral “blood thinners”, such as Pradaxa® (Dabigatran) and Xarelto® (Rivaroxaban): (a) no need for monitoring of its “blood thinning” effect (i.e. no need to determine INRs the way warfarin [Coumadin®, Jantoven®] need to be monitored), (b) no influence of vitamin K in the diet on blood levels, (c) active within a few hours of being taken as a tablet, and (c) out of the blood within approximately 1 1/2 days after stopping to take it, so easier to manage before surgeries and procedures, such as colonoscopies.

As for DVT and PE treatment: large clinical studies (phase 3) comparing Apixaban with standard treatment with warfarin are ongoing ( Apixaban still has quite some way to go before it may come onto the US market, but it is nice to see that a variety of these new “blood thinners” (Summary table) are moving forward towards potentially coming onto the market.

Support Forum:  Questions or comments about Eliquis? Go to the online Clot Connect Support Forum, category “Anticoagulant Use (Blood Thinners)”.

Addendum:  On Aug 28th, 2011, the large atrial fibrillation trial comparing Apixaban with warfarin was published in the NEJM.  A new blog entry discussing this trial can be found here.


Disclosure: I have no financial disclosures relevant to the content of this blog post.

Last updated: Aug 28th, 2011

Tags: , , , ,

Comments are closed.